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Background Parkinson’s disease (PD) is often accompanied by non-motor complications, such as 
dementia, depression, and psychotic symptoms, which worsen the prognosis and increase the personal 
and socioeconomic burden of disease. Prevalence estimates of these complications are quite variable 
and are lacking for the outpatient care sector.  
Methods As part of a larger, nationwide, cross-sectional epidemiological study in n=315 neurological 
outpatient settings in Germany, this paper estimates the frequency of dementia and cognitive 
impairment in n=873 outpatients meeting the UK Brain Bank criteria for idiopathic PD. Assessments 
were based on a clinical interview and neuropsychological assessments, including the Hoehn & Yahr 
rating and Unified Parkinson’s Disease Rating Scale (UPDRS). Cognitive impairment was assessed by 
the Mini-Mental State Exam (MMSE), Clock Drawing Test (CDT) and the Parkinson 
Neuropsychometric Dementia Assessment (PANDA) and the clinician’s diagnosis of dementia was 
based on the diagnostic criteria of DSMIV. Results Using standardized cutoff scores, the prevalence of 
cognitive impairment in the study sample as measured by various methods was 17.5% by MMSE (≤ 
24), 41.8% by CDT (≥ 3), 43.6% by PANDA (≤ 14), and 28.6% met the DSM-IV criteria for 
dementia. All estimates increased with age and PD severity. Gender was an inconsistent contributor 
while illness duration had no significant impact on cognition. Multiple regression analyses revealed 
PD severity to be the strongest predictor of dementia risk (OR=4.3; 95 % CI: 2.1–9.1), while 
neuropsychiatric syndromes had independent, although modest additional contributions (OR=2.5, 95% 
CI: 1.6–3.8).  
Conclusion Estimates of cognitive impairment and dementia in PD patients are largely dependent on 
the diagnostic measure used. Using established clinical diagnostic standards for dementia the overall 
rate on routine outpatient neurological care is 28.6%, but using more sensitive neuropsychological 
measures, rates for cognitive impairment might be up to 2-fold higher. The MMSE revealed strikingly 
low sensitivity. Neuropsychiatric syndromes, in addition to PD severity and age, have an independent 
– although modest – additional contribution to patients’ risk for cognitive impairment and dementia.  
 





Parkinson’s disease (PD) is one of the most common neurodegenerative disorders of late life, 
with an estimated prevalence of 2–3% among people 65 years old and over, and as high as 
10% among those 80 years old and over [6]. Although PD is primarily characterized by 
resting tremor, bradykinesia, rigidity, and postural instability, non-motor symptoms such as 
cognitive impairment, dementia and depression may contribute to a more malignant course of 
illness, increase the risk of nursing home placement, and exacerbate personal and 
socioeconomic burden [4, 16, 19]. Cognitive impairment and dementia (Parkinson’s Disease 
dementia, PDD) have been highlighted as particularly common non-motor complications. 
There is considerable variation in the reported prevalence of PDD, making it difficult to 
accurately estimate its specific age, gender and illness duration- related characteristics. For 
example, the estimated prevalence of cognitive impairment in cross-sectional investigations of 
PDD ranges from 20–44%, constituting an approximate 3- to 6-fold increased risk for PD 
patients as compared to non-PD patients [2, 12]. The cumulative incidence of dementia 
reported in a longitudinal study by Aarsland et al. was 52% after 4 years and nearly 80 % after 
8 years [1]. Variations in findings are most likely due to differences in study population (e.g. 
specialized clinics versus inpatient facilities), sampling procedures (e.g. age range), and 
sample size, as well as use of different diagnostic instruments, criteria and designs. Thus, the 
prevalence of cognitive impairment and dementia in PD at different stages and ages remains 
unclear. Similarly the report of other clinically relevant symptoms, such as depression and 
psychosis, and their impact is incomplete, as only a few studies have comprehensively 
examined the associations between these various non-motor complications and PD. Another 
noteworthy deficit is a lack of estimates derived from neurological outpatient settings in 
routine care. Such data are of interest for improved care and a more adequate provision of 
treatment resources.  
With this background, the German Study on Epidemiology of Parkinson’s Disease with 
Dementia (GEPAD) was launched to provide more comprehensive data on the epidemiology 
of non-motor symptoms among patients with PD treated in the neurological outpatient sector. 
Particular focus was placed on the estimation of the prevalence of dementia and cognitive 
impairment (by various methods), the assessment of depressive and psychotic symptoms, and 






 Design and sampling procedure The GEPAD is a large-scale, nationwide, cross-sectional, 
epidemiological study of the frequency of cognitive impairment, dementia, and depressive 
and psychotic symptoms in an unselected sample of n=1,749 outpatients with parkinsonian 
syndromes. Patients were recruited from a national representative sample of n=315 office-
based neurologists in Germany (Fig. 1). In order to obtain an unbiased selection of PD 
patients, physicians were first requested in a pilot study [28] to enroll all their PD patients on 
one pre-selected day. For the main study that took place on a pre-determined study day during 
the period of September-October 2005, at least five randomly chosen attending patients with 
parkinsonian syndromes were approached and recruited. The ethics committee of the Medical 
Faculty of the TU Dresden (No. EK140082005) approved the study. Participating patients or 
their caregivers gave written informed consent to be assessed according to the study protocol. 
The study center was blinded to patient identity. 
Patients of all ages with the clinician’s diagnosis of Parkinsonian syndromes were eligible. 
Exclusion criteria were minimal to reflect as much as possible the situation in routine care. 
Thirty-nine patients (2.2% of total sample) were excluded because of ethical reasons, because 
of the acute severity of the patients’ health condition (i.e. referral to hospital), which 
prohibited the administration of the assessment interview. One-hundred thirty-nine (7.9%) 
were excluded, because the physicians dealt with other more acute medical problems (e.g. 
acute patient emergencies) of the patient on the study day. Eighty-nine patients (5.1 %) did 
not give written informed consent for participation and n=33 patients (1.9%) were excluded 
for other reasons (e.g. language issues, patients with severe deficits in seeing or hearing). The 
final response rate among all eligible patients with parkinsonism was 82.3% (n=1,449).  
For the purpose of this paper, we limited the analyses to the more diagnostically homogenous 
group of patients meeting the UK Brain Bank criteria for idiopathic PD [14]. We used a 
standardized diagnostic appraisal for all patients which was bradykinesia and at least 1 of 3 
additional cardinal signs (resting tremor, rigidity, and postural instability). Diagnosis of 
idiopathic PD additionally required the presence of at least 3 of the following signs: 
asymmetric onset, resting tremor, substantial levodopa response, and disease duration ≥ 10 
years. Patients with cerebellar signs, early severe dementia with disturbances of memory, 
language and praxis or other symptoms precluding the diagnosis of idiopathic Parkinson were 
excluded. In total, n=873 out of the n=1,449 patients met these study criteria.   
 Study instruments After being trained and supported by monitors, participating physicians 
examined all patients using a standardized interview and an assessment battery. Only 
established robust assessment tools that are used in physicians’ daily practice were utilized. 
The battery contained 3 sections. Section A documented patient demographics such as age, 
gender, marital status, and living situation. Section B documented PD diagnostic status, 
incorporating the Clinical Global Impression scale (CGI) of PD severity, the Hoehn & Yahr 
scale (HY) [13], and parts I (Mentation, Behavior, and Mood), II (Activities of Daily Living), 
and IV (Complications) of the Unified Parkinson’s Disease Rating Scale (UPDRS) [10], and 
recording information about age of PD onset, presence of neurological symptoms, and 
concomitant disorders. Section C consisted of scales and ratings for neuropsychiatric 
complications.  
Cognitive status was assessed with the Mini Mental State Exam (MMSE) and the Clock-
Drawing Test (CDT) [11, 26]. Any score ≤ 24 points in MMSE (30 maximum) or ≥ 3 in CDT 
(6 maximum with: 1=best, 6=worst performance) was considered an appropriate cutoff for 
determination of cognitive impairment [32]. A randomly selected subsample of n=289 
patients was additionally tested with the Parkinson Neuropsychometric Dementia Assessment 
(PANDA), a new psychometric tool with high sensitivity. The structure and the psychometric 
properties of the PANDA instrument as well as the underlying theory have been described in 
detail in recent publications [17, 18]. In short, the PANDA assesses functions that are 
typically affected in PD on five subscales (word pair associate learning with immediate (task 
one) and delayed recall (task five), alternating verbal fluency task (task two), visuospatial task 
(task three) and working memory and attention task (task four) – for a maximum score of 30 
points. If test results are ≥ 18 points, this reflects a normal cognitive function level, 15–17 
points suggest “mild cognitive dysfunctions” and any score below 15 indicates “severe 
cognitive impairment”, indicative of dementia.  
The clinical diagnosis of dementia was based on the DSM-IV criteria [5] as assessed in the 
clinical interview in part A. Severity for both, dementia and PD were rated by the physician 
using the 7-point Clinical Global Impression (CGI) scale [25]. Depression was screened with 
the Montgomery-Asberg Depression Rating Scale (MADRS); patients with a score ≥ 14 (60 
maximum) were classified as depressed [20, 22, 23]. Presence of any additional psychotic 
symptoms was rated by the physician on a symptom list.  
The sequence of administration of the evaluation tools was the same for all patients. Quality 
assurance was checked by random quality assessment by study monitors in a random subset 
of 12% of all assessments. Data quality was checked in the study center, all patient records 
were checked for completeness and consistency before entry. All clock and pentagon 
drawings (i.e. the “copy” task in the MMSE) were independently rated by two blinded 
experienced clinicians. In case of discrepancy between their and the physicians’ ratings (8 %) 
a consensus rating was used.  
 Data analysis Primary outcome variables were the degree of cognitive impairment based on 
the MMSE, CDT and PANDA score, and DSM-IV-based diagnosis. Associations between 
these outcomes and categorical predictor variables were investigated by logistic regression 
analyses. Odds ratios (ORs) and 95% confidence intervals (CIs) are reported. The CIs for the 
prevalence estimates were calculated with the biascorrected and accelerated bootstrap method 
[8]. Multivariate regression analyses were used to investigate in a stepwise manner the 
association between dementia (DSM-IV) and depression, psychotic symptoms, and PD 
severity. Statistical inferences were based on a 5% significance level. Because patients were 
clustered in office-based neurological settings, observations within a setting were correlated. 
To account for the stratified sampling, standard errors, CIs, and p-values were calculated 
using the Huber-White sandwich estimator [29]. All statistical analyses were performed with 





Characteristics of the study sample The patients were primarily male (62.1 %), and their mean 
age was 70.5 years. The average PD onset was 63.8 years (Table 1). According to the HY 
scale, 12.3% of patients were stage I, 27.6% were stage II, 40.4% were stage III, and 19.8% 
were past stage III. Most patients were capable of running a household on their own (23.3%) 
or with their spouses (70.4 %) (data not shown).  
Cognitive impairment and dementia In total, 28.6% (95% CI: 25.5–31.7) of patients met 
criteria for dementia according to DSM-IV criteria. Rates of cognitive impairment differed 
markedly by diagnostic measure used. As shown in rates by age group and gender in Fig.2A–
D, impairment rated by MMSE scores (≤ 24) were consistently the lowest (overall 17.5%, 
95% CI: 14.9–20.2), whereas all other methods resulted in substantially higher rates. Using 
the CDT (score ≥ 3), 41.8 % (95 % CI: 38.6–45%) of patients were determined to have 
cognitive impairment, compared to 43.6 % (95% CI: 37.8–49.4) using the PANDA (score ≤ 
14). The frequency of dementia and cognitive impairment increased significantly with age 
with all four measures. Except for the CDT where women scored significantly worse than 
men, there were no gender differences. For patients aged ≥ 76 years, the probability of a score 
≥3 was 2-fold higher for females versus males (OR=2.0, 95% CI: 1.2–3.5).  
Table 2 reports the association of these cognitive impairment measures and dementia 
according to DSM-IV respectively with selected sociodemographic predictors. All measures 
were significantly associated with age, lowest rates were found for the youngest (range:8.8 
MMSE to 32.8% PANDA) and highest in the oldest age group (range: 26% MMSE to 51.1% 
PANDA). Patients aged ≥76 years were 4-fold more likely to have dementia than patients 
aged ≤ 65 years (OR=4.0, 95% CI 2.6–6.3). Except for the CDT no association with gender 
was found. In each measure, higher educational status was associated with decreased rate of 
cognitive impairment, however, for the PANDA this association was not significant.  
All four measures were also significantly associated with PD severity (Hoehn & Yahr rating). 
Dementia according to DSM-IV occurred in 10.6% of all patients staged I, in 20.5% of those 
staged II, 30.6% at stage III and 48.2% in patients past stage III (i.e. IV+V, see Table 3). For 
the MMSE, there was a steady increase across stages in the percentage of patients achieving a 
score indicative of cognitive impairment (≤ 24 points), increasing from 7.9% for stage I to 
33.1% for stages IV/V. In comparison, the frequency of cognitive impairment by CDT (score 
≥ 3) and PANDA (score ≤ 14) was higher across stages, increasing from 30.4 % for stage I to 
53.1 % for stage IV/V (PANDA: from 18 % for stage I to 62 % for stage IV/V). Again, the 
gender difference in performance of the CDT was apparent across stages and significant for 
stages II (51.7 % females vs. 22.7 % males) and III (53.7 % females vs. 41.4 % males).  
Using the DSM-IV criteria as the gold standard, we compared sensitivity and specificity for 
the three measures of cognitive impairment. Sensitivity was lowest for the MMSE (50 %) and 
highest for the PANDA (73.2 %). The sensitivity of the CDT was 71.1%. The specificities for 
the MMSE, CDT and PANDA were 94.5%, 69.3% and 71.4%, respectively. In the MMSE 
and CDT, sensitivity was lowest in patients ≤ 65 years (32.3 % and 38.7%) and highest in 
patients aged 71–75 years (MMSE: 60.5%) and ≥ 76 years (CDT: 82.8 %). For PANDA the 
sensitivity rates were 75% (≤65 years), 61.3 % (66–70 years), 88.9% (71–75 years) and 75% 
(≥76 years). On all three measures, specificity decreased with increasing age.  
Since it has been assumed that measurements of cognitive impairment by test with motor 
components could be influenced by the motor dysfunction of PD, we also investigated 
whether the association of PD severity with cognitive impairment is influenced in this regard. 
We therefore used two regression analyses with each MMSE score and CDT score as a 
dependent dimensional variable and the PD severity as independent variable with HY stage I 
as reference. For the MMSE the mean total score loss across HY stages II, III and IV/V were 
∆=–0.2, ∆=–1.0 and ∆=–2.8, respectively. When controlling for motor dysfunction (UPDRS 
item “handwriting”), the mean score differences across these stages were ∆=–0.0, ∆=–0.8 and 
∆=–2.4. Similar results were obtained for the CDT with mean score increments of ∆=0.1, 
∆=0.3 and ∆=0.8 prior to and ∆=0.0, ∆=0.3 and ∆=0.6 after adjusting for motor 
complications. Overall, these results suggest that the consideration of motor dysfunction 
attenuates the performance in the tests only marginally.  
Frequency and interactions with other neuropsychiatric symptoms Overall, 26.2% of subjects 
exceeded the MADRS depression cut-off score. Women were significantly more likely to be 
depressed (males 21.9%, females 33.1%; OR=1.8, 95% CI 1.3–2.4). Nineteen percent of 
patients were determined to have at least one psychotic symptom; there was no significant 
gender difference (males 20.1%, females 17.2 %). Hallucinations were the only symptom to 
increase significantly with age, with highest rates in patients aged ≥ 76 years (16.9 %).  
Table 3 shows the number, percentage, and crude ageadjusted associations of selected 
predictor PD and neuropsychiatric variables with dementia and the three measures of 
cognitive impairment, respectively. As mentioned previously, for all four measures, the 
frequency of dementia and cognitive impairment was strongly associated with PD severity. 
Age of PD onset and PD duration were not associated with a higher probability of dementia or 
cognitive impairment, except for the PANDA, which was significantly inversely associated 
with age of PD onset (OR=0.3; 95% CI: 0.1–0.8). Dementia and cognitive impairment were 
also strongly associated with depression according to MADRS (for dementia OR=3.7, 95% CI 
2.6–5.2) and psychotic symptoms (OR=4.1, 95% CI 2.8–6.0). It is noteworthy that the 
association between PANDA and depression as well as psychotic symptoms was somewhat 
weaker compared to all measures.  
Based on these significant associations, we examined the combined effect of depressive and 
psychotic symptoms and PD severity on the risk of dementia, taking age into account. A 
multiple stepwise logistic regression model was used, with only age entered initially 
(OR=1.06, 95% CI: 1.04–1.08, R2=0.042). Addition of HY stage significantly increased the 
predictive value (R2=0.086, highest for stage IV/V with an OR=6.26, 95% CI: 3.11–12.62). 
To determine which of the variables (age, PD severity (HY) or disease duration) had the 
greatest impact on risk of cognitive impairment, we entered these variables in a separate 
logistic regression model. Our results indicate that severity of PD has a higher impact on the 
probability of being diagnosed with dementia (OR=2.13, 95% CI: 1.68–2.70) than did age 
(OR=1.06, 95% CI: 1.03–1.08), whereas the effect of disease duration remained insignificant 
(OR=1.01, 95% CI: 0.98–1.04). Depressive symptoms determined by the MADRS 
(R2=0.123) and presence of any psychotic symptom (R2=0.142) were entered in steps three 
and four. The inclusion of neuropsychiatric symptoms slightly attenuated the effect of PD 
severity, thus improving the prediction of dementia. We also examined whether the number of 
psychotic symptoms markedly improved the prediction accuracy, and found no effect 
(R2=0.145). Thus, approximately the same amount of variance was explained by the addition 








We investigated the frequency of cognitive impairment, clinically diagnosed dementia and 
other neuropsychiatric disorders (depression and psychotic symptoms) in a large unselected 
nationwide sample of 873 PD patients visiting office-based neurologists in Germany. Overall, 
the findings highlight the considerable burden of nonmotor complication in patients with PD. 
Strengths of the study include the large sample size, the representative sample for the 
outpatient sector, and the use of various established measures for the assessment of cognitive 
impairment and neuropsychiatric symptoms, allowing a broader and more comprehensive 
epidemiological characterization. The limitations are the cross-sectional design, and due to the 
study being conducted in routine care, the partial lack of differential diagnostic sophistication. 
Also other risk factors, such as potentially relevant lab markers (e.g. apolipoprotein E4) could 
not be considered. Further, with regard to the use of psychometric tools, we were 
predominantly limited to the use of instruments that were not specifically developed for PD 
patients though were robust and featured established reliability and validity. Despite this and 
the implementation of considerable quality assurance measures, however, we can not exclude 
the possibility that the administration of diagnostic tools is more variable as compared to 
more strictly controlled clinical-experimental designs. Yet, this potential variability is 
unlikely to affect the findings systematically, due to the nature of the standardized instruments 
as well as the representative sampling strategy, prohibiting systematic selection bias on behalf 
of the participating doctors. Also the current paper is the first publication of the GEPAD main 
study, restricting in this first paper the possibility of a more detailed presentation of the 
neuropsychological and neuropsychiatric findings and their implications at this point.  
The estimates of cognitive impairment and dementia in PD patients are partly dependent on 
the diagnostic measure used and are substantial with at least one third of patients affected. 
According to physicians’ assessments, 28.6% of patients met the DSM-IV diagnostic criteria 
for dementia. However, neuropsychological instruments revealed considerably higher rates 
for clinically significant cognitive impairment of 41.8% (CDT) and 43.6% (PANDA). Both 
measures, designed as simple and robust screening tools, also revealed good sensitivities 
(CDT: 71.1%, PANDA: 73.2%) and appropriate specificities (69.3 % and 71.4 %). In 
contrast, the MMSE overlooks a considerable proportion of patients with clinically diagnosed 
dementia when the suggested cutoff score (≤ 24) is used, thus revealing lower sensitivity (50 
%), questioning the utility of the MMSE for screening of dementia in PD patients.  
The finding of overall at least 28% of clinically diagnosed dementia in the whole sample and 
considerable, up to two-fold higher rates as determined by neuropsychological instruments, is 
consistent with the upperbound estimates in previous studies [9, 15]. The substantially higher 
rates in the older patients (range 41.0–56.8 %) additionally underscore the evidence from 
prospective-longitudinal studies [1] substantiating the conclusion that the risk of clinically 
significant dementia is considerably increased in PD versus non-PD patients.  
Several factors were shown to be associated with increased rates of cognitive decline in PD. 
Age and particularly severity (Hoehn & Yahr staging) of PD symptoms were associated with 
the clinical diagnosis of dementia and the degree of cognitive impairment in our sample [1, 
33]. Cognitive impairment according to the CDT was approximately 2 times more frequent in 
patients in the oldest age group than in patients in the youngest age group. For the PANDA, 
which was administered to a subsample of patients, the frequency of cognitive impairment 
increased from almost one third of patients aged ≤65 to more than every other patient aged ≥ 
76 being afflicted. The frequency of dementia according to DSM-IV criteria was almost 3 
times higher in patients aged ≥76 than in those aged ≤ 65 and the same held true for the rates 
of the MMSE.  
Logistic regression analyses suggest that both age and HY stage have independent effects, 
both contributing to the increased prevalence of cognitive impairment. With the exception of 
the CDT, we did not find a significant effect of either gender or age of PD onset, when 
adjusting for age. We also could exclude the possibility that the high rates of cognitive 
impairment could be largely attributed to the considerable motor component of PD. One could 
suspect that increased rates of cognitive impairment in the neuropsychiatric instruments could 
largely be due to the patient’s motor disturbance and his/her failure to complete complex 
motor-related tasks in instruments like the MMSE and CDT. Although a statistical 
examination of this issue revealed some indication of this, the effect size is small and did not 
change considerably the rates. Furthermore, if such an effect were substantial, one would 
expect lower rates in the PANDA, which does not contain any such complex motor tasks.  
This leads to the question of how high the true rates of clinically significant cognitive 
impairment are and what type of diagnostic measure reflects this best and with the highest 
sensitivity, in the presence of cognitive impairment. Accepting the differential diagnostic 
imprecision inherent in the study, the clinician’s diagnosis according to DSM-IV can be 
regarded as the lower bound estimate, due to the strict diagnostic criteria, that most likely do 
not yet reflect the presence of PD-specific cognitive impairment in early stages. The MMSE, 
also frequently used as an epidemiological tool to assess cognitive impairment, in contrast 
reveals the lowest estimates, is largely dependent on age, and disturbingly compares poorest 
to the clinical diagnosis of dementia according to DSM-IV. This is in line with more general 
concerns, that the MMSE with its lesser accentuation of executive functions is probably not 
an appropriate screening tool for PD patients. In contrast the CDT yielded higher rates of 
cognitively impaired patients with a somewhat weaker specificity than the PANDA. The 
PANDA seems to be a quite sensitive instrument, particularly in younger PD patients, with a 
good sensitivity and specificity match as compared to clinical diagnoses in higher age groups. 
It might be regarded as the upper-bound estimate. In addition it is noteworthy that the scale 
minimizes the impact of motor disturbances on performance, as it demands only minimally 
motor responses (i.e. no writing or drawing necessary).  
Multiple factors could have contributed to the noticeable differences in frequencies 
determined using the MMSE versus the CDT, PANDA and the clinical diagnosis. First, it is 
still under discussion if PD and PDD have the same underlying pathogenesis, that is, that 
cognitive abilities always deteriorate with advancing disease [21]. Thus, the relatively small 
proportion of advanced PD patients in our study sample could have contributed to the low 
frequencies of dementia. However, if this were true, the frequencies of cognitive impairment 
estimated with the CDT and clinical diagnosis should also have been low. Second, PD 
patients might perform poorly on drawing tasks as a result of their physical disabilities and 
not merely their cognitive deterioration. We think that this hypothesis can be excluded 
because tremor is not considered in the MMSE or CDT ratings. It is also possible that the 
MMSE is not diagnostic of the cognitive impairment typical for PD patients, as subcortical 
dementias (such as PDD) are understood to impact visuospatial abilities more than other 
abilities such as short-term memory [27]. Thus, as only one item in the MMSE refers to 
drawing, the total score is less sensitive to visuospatial deficits than is the CDT, which more 
extensively tests visuospatial ability. Visuoconstructional difficulties have been reported to be 
present early in the course of Lewy body disease and may also relate to fronto-subcortical 
dysfunction [7, 24]. Indeed, our study supports previous findings of drawing difficulties in PD 
patients, especially on the CDT and related gender effects [31]. Finally, comorbidity of 
dementia with advanced age and disease stage may contribute to the observation of visuo- 
perceptive deficits by virtue of the presence of temporoparietal Alzheimer pathology.  
Idiopathic PD was also found to be associated with a substantial burden of depressive and 
psychotic symptoms: 21.6% of all patients in the sample exceeded the MADRS cut off for 
clinically significant depression and 19% had psychotic features, most frequently 
hallucinations. Both complications are known to be frequent complications of PD, and our 
estimates do not differ substantially from previous estimates [3, 30, 34]. In multiple 
regression analyses we could show, however, that depressive and psychotic symptoms reveal 
no substantial effects on the estimation of cognitive impairment. Although depression adds an 
independent statistical contribution of increased rates of cognitive impairment and dementia, 
the overall effect is small and would not change dramatically the rates of cognitive 
impairment, if the influence of depressive symptoms on measures of cognitive impairment 
were discarded. Furthermore, the lack of a consistent age effect for depressive and psychotic 
symptoms argues against the possibility that rates of cognitive impairment and dementia are 
largely explained by the presence of these symptoms. Instead descriptively and discarding 
etiopathogenetic pathways, the findings are more consistent with depression and psychotic 
experiences being separate phenomena adding however substantially to the patient’s overall 
burden of disease and suffering.  
Our findings are the first to provide estimates of dementia, cognitive impairment and 
neuropsychiatric complications based on the neurological day-to-day care sector in Germany, 
taken from a large representative sample of PD outpatients in office-based settings. However, 
our results must be interpreted with caution. The first and most important caveat is the 
restriction to office-based neurologists; prevalence estimates should only be interpreted with 
regard to this target population. Because this was not a community survey, the true prevalence 
of dementia in PD would necessarily be higher if more severe cases, such as hospitalized 
patients or nursing homes patients, were included. Likewise, PD patients in very early stages 
largely suffer from non-specific somatic symptoms (e.g. backache, stiffness) and thus are 
more likely to be under medical treatment by general practitioners than by neurologists. The 
latter might have resulted in overall lower estimates. Furthermore, we focused in this paper on 
idiopathic PD in order to describe a homogenous disease group, as results for the total sample 
are under review.  
In conclusion, our study indicates that cognitive impairment and neuropsychiatric symptoms 
in PD are common in the neurological outpatient sector and occur frequently at young age, 
and in early stages of the disease. Screening for these complications should use sensitive 
neuropsychological tools for PD patients, like the PANDA, followed by a careful clinical 
diagnostic work up. The MMSE does not perform well in this respect, leading to a 
considerable underestimation of even clinically established patients with PD.  
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